This is our Regulatory Landscape newsletter for May 2025 with our monthly insights on the evolving market for Regulatory professionals.
For the month of April there were approximately 78 new Regulatory positions posted at smaller and mid-sized biopharma companies in the US. This is down 9% from March and down 19% from last April.
63% of these new positions in April were in Clinical Regulatory Strategy and 19% were in CMC Regulatory, 10% were in Advertising, Promotions & Labeling, and 8% in Regulatory Operations. Roughly 56% of these roles were at Director level and above. There was only one new Regulatory VP/SVP position posted in April – this is the lowest number of VP/SVP roles we have seen since we started tracking Regulatory job postings in 2020.
49% of the new Regulatory positions in April were listed as Onsite, 32% were posted as Remote and 19% were Hybrid (remote/onsite). 36% of the April Regulatory positions were in California, 33% were in Massachusetts, and 19% were in the NJ/NY/PA area.
There were layoffs announced at 19 biopharma companies in April.
This month we are working on the following searches for our clients:
- Vice President of Regulatory Affairs – Oncology (Hybrid, Boston Area)
- Regulatory Affairs Sr. Director/Exec Director – Rare Disease (Remote)
- Regulatory Advertising & Promotions Associate Director or Senior Manager (Greater Boston or Philadelphia areas)
- Senior Regulatory Affairs Consultant – Oncology (SF Bay Area)
In April Dennis Partners surveyed Regulatory Affairs professionals across the pharmaceutical and biotech industries to assess the impact of the recent layoffs at FDA and HHS. You can see the results of that study here: https://dennispartners.com/market-research/how-fda-nih-hhs-cdc-layoffs-are-impacting-industry-what-the-regulatory-affairs-community-is-saying/
Please consider us for your Regulatory hiring or let us know if you are considering a career change soon.